1. Global Rheumatoid Arthritis Drugs Market
2014-2018
Published on: July 2014
No. of Pages: 94
Mail us: sales@reportsandintelligence.com
Detailed report at: http://www.reportsandintelligence.com/global -
rheumatoid-arthritis-drugs-2014-2018-market
Website: http://www.reportsandintelligence.com

2. Rheumatoid Arthritis is a chronic disease that leads to inflammation and pain in
the human body's joints such as wrists, fingers, knees, feet, and ankles. In
addition, it causes inflammation of the tissues that surround the joints and in
other organs. The symptoms of RA begin slowly, usually just mild pain around the
joints coupled with stiffness and fatigue, and in the later stages it causes
inflammation of the joints. It can occur at any age, even in children, which is
called juvenile arthritis. The disease is three times more common in women than
in men. Genetic and environmental elements are known to contribute in the
development of RA.
TechNavio's analysts forecast the Global Rheumatoid Arthritis Drugs market will
grow at a CAGR of 4.09 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global
Rheumatoid Arthritis Drugs market for the period 2014-2018. To calculate the
market size, the report considers the revenue generated from the sales of various
drugs used in the treatment of RA that are available in the market. The Global
Rheumatoid Arthritis Drugs market can be divided into two segments:
Symptomatic and DMARDs.
TechNavio's report, the Global Rheumatoid Arthritis Drugs Market 2014-2018, has
been prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the Americas and the EMEA and APAC regions; it also
covers the Global Rheumatoid Arthritis Drugs market landscape and its growth
prospects in the coming years. The report also includes a discussion of the key
vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC

3. Key Vendors
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Janssen Pharmaceuticals Inc.
• Pfizer Inc.
Other Prominent Vendors
• AB Science SA
• Astellas Pharma Inc.
• AstraZeneca plc
• Biogen Idec Inc.
• Boehringer Ingelheim GmbH
• Celgene Corp.
• Daiichi Sankyo Co. Ltd.
• Eli Lilly & Co.
• GE Healthcare Co.
• Genmab A/S
• GSK plc
• Incyte Corp.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Novartis AG
• Novo Nordisk A/S
• Rigel Pharmaceuticals Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• UCB SA
• Vertex Pharmaceuticals Inc.
Key Market Driver
• Increasing Aging Population
• For a full, detailed list, view our report.

4. Key Market Challenge
• High Cost of RA Treatment
• For a full, detailed list, view our report.
Key Market Trend
• Increase in R&D Activities
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Detailed report at: http://www.reportsandintelligence.com/global-rheumatoid-
arthritis-drugs-2014-2018-market

5. Table of Content
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. Competitive Assessment of Top Drugs
08. Five Forces Analysis
09. Market Segmentation by Category
10. Geographical Segmentation
11. Buying Criteria
12. Rate of Incidence and Prevalence
12.1.1 US
12.1.2 UK
12.1.3 Asia
13. Pipeline Snapshot
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
Full TOC at: http://www.reportsandintelligence.com/global-rheumatoid-arthritis-
drugs-2014-2018-market/table-of-contents

6. 20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 AbbVie
21.1.1 Key Facts
21.1.2 Business Description
21.1.3 Product Segmentation
21.1.4 Revenue by Product Line
21.1.5 Revenue Comparison 2012 and 2013
21.1.6 Revenue by Geographical Segmentation
21.1.7 Business Strategy
21.1.8 Key Developments
21.1.9 SWOT Analysis
21.1.10 Strengths
21.1.11 Weaknesses
21.1.12 Opportunities
21.1.13 Threats
21.2 Amgen
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Product Segmentation by Revenue 2013
21.2.4 Geographical Segmentation by Revenue 2013
21.2.5 Business Strategy
21.2.6 Key Information
21.2.7 SWOT Analysis
21.2.8 Strengths
21.2.9 Weaknesses
21.2.10 Opportunities
21.2.11 Threats
21.3 Bristol-Myers Squibb
21.3.1 Key Facts
21.3.2 Business Overview

7. 21.3.3 Product Segmentation
21.3.4 Sales by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.3.8 Strengths
21.3.9 Weaknesses
21.3.10 Opportunities
21.3.11 Threats
21.4 F. Hoffmann La Roche
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.4.9 Strengths
21.4.10 Weaknesses
21.4.11 Opportunities
21.4.12 Threats
21.5 Janssen Pharmaceuticals
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation
21.5.4 Business Strategy
21.5.5 Key Developments
21.5.6 SWOT Analysis
21.5.7 Strengths
21.5.8 Weaknesses
21.5.9 Opportunities
21.5.10 Threats
21.6 Pfizer
21.6.1 Key Facts
21.6.2 Business Overview
21.6.3 Business Segmentation by Revenue 2013

8. 21.6.4 Business Segmentation by Revenue 2012 and 2013
21.6.5 Sales by Geography
21.6.6 Business Strategy
21.6.7 Key Developments
21.6.8 SWOT Analysis
21.6.9 Strengths
21.6.10 Weaknesses
21.6.11 Opportunities
21.6.12 Threats
22. Other Reports in this Series
Full TOC at: http://www.reportsandintelligence.com/global-rheumatoid-arthritis-
drugs-2014-2018-market/table-of-contents
Contact Us:
Cathy Viber
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Fax: +1 (855) 550-5975
Mailto: sales@reportsandintelligence.com
Web: http://www.reportsandintelligence.com/
Blog: http://www.reportsandintelligence.blogspot.com/